These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 32920471)

  • 1. Association of plasma YKL-40 with brain amyloid-β levels, memory performance, and sex in subjective memory complainers.
    Vergallo A; Lista S; Lemercier P; Chiesa PA; Zetterberg H; Blennow K; Potier MC; Habert MO; Baldacci F; Cavedo E; Caraci F; Dubois B; Hampel H; ; ;
    Neurobiol Aging; 2020 Dec; 96():22-32. PubMed ID: 32920471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Astrocyte-specific knockout of YKL-40/Chi3l1 reduces Aβ burden and restores memory functions in 5xFAD mice.
    Zeng X; Cheung SKK; Shi M; Or PMY; Li Z; Liu JYH; Ho WLH; Liu T; Lu K; Rudd JA; Wang Y; Chan AM
    J Neuroinflammation; 2023 Dec; 20(1):290. PubMed ID: 38042775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease.
    Craig-Schapiro R; Perrin RJ; Roe CM; Xiong C; Carter D; Cairns NJ; Mintun MA; Peskind ER; Li G; Galasko DR; Clark CM; Quinn JF; D'Angelo G; Malone JP; Townsend RR; Morris JC; Fagan AM; Holtzman DM
    Biol Psychiatry; 2010 Nov; 68(10):903-12. PubMed ID: 21035623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
    Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H;
    Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PTI-125 Reduces Biomarkers of Alzheimer's Disease in Patients.
    Wang HY; Pei Z; Lee KC; Lopez-Brignoni E; Nikolov B; Crowley CA; Marsman MR; Barbier R; Friedmann N; Burns LH
    J Prev Alzheimers Dis; 2020; 7(4):256-264. PubMed ID: 32920628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CSF YKL-40 and pTau181 are related to different cerebral morphometric patterns in early AD.
    Gispert JD; Monté GC; Falcon C; Tucholka A; Rojas S; Sánchez-Valle R; Antonell A; Lladó A; Rami L; Molinuevo JL
    Neurobiol Aging; 2016 Feb; 38():47-55. PubMed ID: 26827642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age.
    Sutphen CL; Jasielec MS; Shah AR; Macy EM; Xiong C; Vlassenko AG; Benzinger TL; Stoops EE; Vanderstichele HM; Brix B; Darby HD; Vandijck ML; Ladenson JH; Morris JC; Holtzman DM; Fagan AM
    JAMA Neurol; 2015 Sep; 72(9):1029-42. PubMed ID: 26147946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. YKL-40 as a Potential Biomarker and a Possible Target in Therapeutic Strategies of Alzheimer's Disease.
    Muszyński P; Groblewska M; Kulczyńska-Przybik A; Kułakowska A; Mroczko B
    Curr Neuropharmacol; 2017; 15(6):906-917. PubMed ID: 28183245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer's disease in a memory clinic cohort.
    Kester MI; Teunissen CE; Sutphen C; Herries EM; Ladenson JH; Xiong C; Scheltens P; van der Flier WM; Morris JC; Holtzman DM; Fagan AM
    Alzheimers Res Ther; 2015 Sep; 7(1):59. PubMed ID: 26383836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease.
    Vergallo A; Mégret L; Lista S; Cavedo E; Zetterberg H; Blennow K; Vanmechelen E; De Vos A; Habert MO; Potier MC; Dubois B; Neri C; Hampel H; ;
    Alzheimers Dement; 2019 Jun; 15(6):764-775. PubMed ID: 31113759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between β-Secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer's disease.
    Alcolea D; Carmona-Iragui M; Suárez-Calvet M; Sánchez-Saudinós MB; Sala I; Antón-Aguirre S; Blesa R; Clarimón J; Fortea J; Lleó A
    J Alzheimers Dis; 2014; 42(1):157-67. PubMed ID: 24820015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chitinase-3-like 1 protein (CHI3L1) locus influences cerebrospinal fluid levels of YKL-40.
    Deming Y; Black K; Carrell D; Cai Y; Del-Aguila JL; Fernandez MV; Budde J; Ma S; Saef B; Howells B; Bertelsen S; Huang KL; Sutphen CL; Tarawneh R; Fagan AM; Holtzman DM; Morris JC; Goate AM; Dougherty JD; Cruchaga C
    BMC Neurol; 2016 Nov; 16(1):217. PubMed ID: 27832767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrospinal fluid levels of YKL-40 in prodromal Alzheimer's disease.
    Wang L; Gao T; Cai T; Li K; Zheng P; Liu J;
    Neurosci Lett; 2020 Jan; 715():134658. PubMed ID: 31794792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inflammation, Amyloid, and Atrophy in The Aging Brain: Relationships with Longitudinal Changes in Cognition.
    Sala-Llonch R; Idland AV; Borza T; Watne LO; Wyller TB; Brækhus A; Zetterberg H; Blennow K; Walhovd KB; Fjell AM
    J Alzheimers Dis; 2017; 58(3):829-840. PubMed ID: 28505968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amyloid beta-positive subjects exhibit longitudinal network-specific reductions in spontaneous brain activity.
    Avants BB; Hutchison RM; Mikulskis A; Salinas-Valenzuela C; Hargreaves R; Beaver J; Chiao P;
    Neurobiol Aging; 2019 Feb; 74():191-201. PubMed ID: 30471630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glial activation and inflammation along the Alzheimer's disease continuum.
    Nordengen K; Kirsebom BE; Henjum K; Selnes P; Gísladóttir B; Wettergreen M; Torsetnes SB; Grøntvedt GR; Waterloo KK; Aarsland D; Nilsson LNG; Fladby T
    J Neuroinflammation; 2019 Feb; 16(1):46. PubMed ID: 30791945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic function of the neuroinflammatory biomarker YKL-40 in Alzheimer's disease and other neurodegenerative diseases.
    Baldacci F; Lista S; Cavedo E; Bonuccelli U; Hampel H
    Expert Rev Proteomics; 2017 Apr; 14(4):285-299. PubMed ID: 28281838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease.
    Alcolea D; Martínez-Lage P; Sánchez-Juan P; Olazarán J; Antúnez C; Izagirre A; Ecay-Torres M; Estanga A; Clerigué M; Guisasola MC; Sánchez Ruiz D; Marín Muñoz J; Calero M; Blesa R; Clarimón J; Carmona-Iragui M; Morenas-Rodríguez E; Rodríguez-Rodríguez E; Vázquez Higuera JL; Fortea J; Lleó A
    Neurology; 2015 Aug; 85(7):626-33. PubMed ID: 26180139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brain Aβ load association and sexual dimorphism of plasma BACE1 concentrations in cognitively normal individuals at risk for AD.
    Vergallo A; Houot M; Cavedo E; Lemercier P; Vanmechelen E; De Vos A; Habert MO; Potier MC; Dubois B; Lista S; Hampel H; ;
    Alzheimers Dement; 2019 Oct; 15(10):1274-1285. PubMed ID: 31627825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Which Episodic Memory Performance is Associated with Alzheimer's Disease Biomarkers in Elderly Cognitive Complainers? Evidence from a Longitudinal Observational Study with Four Episodic Memory Tests (Insight-PreAD).
    Gagliardi G; Epelbaum S; Houot M; Bakardjian H; Boukadida L; Revillon M; Dubois B; Dalla Barba G; La Corte V;
    J Alzheimers Dis; 2019; 70(3):811-824. PubMed ID: 31282413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.